These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22111489)

  • 1. Benefits of ticagrelor debated as antiplatelet class approaches generic market.
    Morrow T
    Manag Care; 2011 Oct; 20(10):77-8. PubMed ID: 22111489
    [No Abstract]   [Full Text] [Related]  

  • 2. Ticagrelor for acute coronary syndrome?
    Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
    Göddertz R
    MMW Fortschr Med; 2013 Apr; 155(7):16. PubMed ID: 23668163
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
    Capodanno D; Dharmashankar K; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):151-8. PubMed ID: 20136601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiplatelet agents: why they are needed.
    Franchini M; Mannucci PM
    Eur J Intern Med; 2009 Dec; 20(8):733-8. PubMed ID: 19892299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
    Doggrell SA
    IDrugs; 2009 May; 12(5):309-17. PubMed ID: 19431096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A delicate balance: the cost effectiveness of new antiplatelet agents.
    Kazi DS; Hlatky MA
    J Am Coll Cardiol; 2015 Feb; 65(5):477-9. PubMed ID: 25660926
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
    Ramaraj R; Movahed MR; Hashemzadeh M
    J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
    Gaglia MA; Waksman R
    Circulation; 2011 Feb; 123(4):451-6. PubMed ID: 21242480
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in antiplatelet treatment for acute coronary syndromes.
    Eshaghian S; Shah PK; Kaul S
    Heart; 2010 May; 96(9):656-61. PubMed ID: 19910292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
    Serebruany VL
    Cardiology; 2010; 117(3):231-3. PubMed ID: 21212672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
    Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.